Prognostic Factors for Advanced Epithelial Ovarian Cancer Following Primary Cytoreductive Surgery or Neoadjuvant Chemotherapy

To examine the association between clinicopathological factors and survival in advanced epithelial ovarian, tubal, and primary peritoneal cancers patients who had primary cytoreductive surgery (CRS) and those that received neoadjuvant chemotherapy (NAC). Women who had CRS or NAC between 2008-2017 we...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Asian Pacific Journal of Cancer Prevention 2022-11, Vol.23 (11), p.3791-3799
Hauptverfasser: Nantasupha, Chalaithorn, Muangmool, Tanarat, Charoenkwan, Kittipat
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 3799
container_issue 11
container_start_page 3791
container_title Asian Pacific Journal of Cancer Prevention
container_volume 23
creator Nantasupha, Chalaithorn
Muangmool, Tanarat
Charoenkwan, Kittipat
description To examine the association between clinicopathological factors and survival in advanced epithelial ovarian, tubal, and primary peritoneal cancers patients who had primary cytoreductive surgery (CRS) and those that received neoadjuvant chemotherapy (NAC). Women who had CRS or NAC between 2008-2017 were included. Association between clinical characteristics, pretreatment imaging, serum markers, surgical and pathological factors, and disease recurrence/progression/death was examined in multivariable analysis. Two hundred and three women were recruited in this study (CRS 128 women and NAC 75 women). Median overall survival was 33.7 months for the CRS group and 27.9 months for the NAC group (p=0.04). Median progression-free survival was 14.9 months in the CRS group and 12.1 months in the NAC group (p=0.04). For the CRS group, factors independently associated with increased risk of death included primary peritoneal carcinoma (adjusted hazard ratio [aHR] 6.94), stable disease/progression at treatment completion (aHR 5.97), and initial tumor size of more than 12 cm (aHR 1.87). For the NAC group, stable disease/progression after complete treatment (aHR 6.45) and pre-treatment platelet to lymphocyte ratio of more than 310 (aHR 2.20) were significantly associated with an increased risk of death. NAC appeared to be a good alternative treatment for stage III/IV tubo-ovarian carcinoma. The worse survival outcome associated with primary peritoneal carcinoma and large initial tumor size in the patients who received CRS suggested that NAC could be an attractive option for those with these characteristics.
doi_str_mv 10.31557/APJCP.2022.23.11.3791
format Article
fullrecord <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9930965</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>36444592</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2591-49e26cfe94720ac86cecb302980a2bc52ec5e721c0615daaabd353c7a65ef36f3</originalsourceid><addsrcrecordid>eNpVkdtKAzEQhoMoHqqvIHmBrjlsss2NUBbrAdGCCt6FaXa2jWw3Jbut9MJ3d9tq0asZZvi_GfgIueQskVyp7Go4fsjHiWBCJEImnCcyM_yAnIo00_1Mi_fDP_0JOWuaD8ZSNcjUMTmROk1TZcQp-RrHMK1D03pHR-DaEBtahkiHxQpqhwW9Wfh2hpWHij6vIHqoab7ZRDoKVRU-fT2l4-jnENc0X3d5LJau9SukL8s4xW7a0Z4wQPGx7JAtzWc4Dx0ywmJ9To5KqBq8-Kk98ja6ec3v-o_Pt_f58LHvhDK8nxoU2pVo0kwwcAPt0E0kE2bAQEycEugUZoI7prkqAGBSSCVdBlphKXUpe-R6x10sJ3MsHNZthMoudn_bAN7-39R-ZqdhZY2RzGjVAfQO4GJomojlPsuZ3QqxWyF2I8QKaTm3GyFd8PLv5X3s14D8BrnWjLo</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Prognostic Factors for Advanced Epithelial Ovarian Cancer Following Primary Cytoreductive Surgery or Neoadjuvant Chemotherapy</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Free E- Journals</source><creator>Nantasupha, Chalaithorn ; Muangmool, Tanarat ; Charoenkwan, Kittipat</creator><creatorcontrib>Nantasupha, Chalaithorn ; Muangmool, Tanarat ; Charoenkwan, Kittipat</creatorcontrib><description>To examine the association between clinicopathological factors and survival in advanced epithelial ovarian, tubal, and primary peritoneal cancers patients who had primary cytoreductive surgery (CRS) and those that received neoadjuvant chemotherapy (NAC). Women who had CRS or NAC between 2008-2017 were included. Association between clinical characteristics, pretreatment imaging, serum markers, surgical and pathological factors, and disease recurrence/progression/death was examined in multivariable analysis. Two hundred and three women were recruited in this study (CRS 128 women and NAC 75 women). Median overall survival was 33.7 months for the CRS group and 27.9 months for the NAC group (p=0.04). Median progression-free survival was 14.9 months in the CRS group and 12.1 months in the NAC group (p=0.04). For the CRS group, factors independently associated with increased risk of death included primary peritoneal carcinoma (adjusted hazard ratio [aHR] 6.94), stable disease/progression at treatment completion (aHR 5.97), and initial tumor size of more than 12 cm (aHR 1.87). For the NAC group, stable disease/progression after complete treatment (aHR 6.45) and pre-treatment platelet to lymphocyte ratio of more than 310 (aHR 2.20) were significantly associated with an increased risk of death. NAC appeared to be a good alternative treatment for stage III/IV tubo-ovarian carcinoma. The worse survival outcome associated with primary peritoneal carcinoma and large initial tumor size in the patients who received CRS suggested that NAC could be an attractive option for those with these characteristics.</description><identifier>ISSN: 2476-762X</identifier><identifier>ISSN: 1513-7368</identifier><identifier>EISSN: 2476-762X</identifier><identifier>DOI: 10.31557/APJCP.2022.23.11.3791</identifier><identifier>PMID: 36444592</identifier><language>eng</language><publisher>Thailand: West Asia Organization for Cancer Prevention</publisher><subject>Carcinoma, Ovarian Epithelial - drug therapy ; Cytoreduction Surgical Procedures ; Female ; Genital Neoplasms, Male ; Humans ; Neoadjuvant Therapy ; Ovarian Neoplasms - drug therapy ; Ovarian Neoplasms - surgery ; Prognosis</subject><ispartof>Asian Pacific Journal of Cancer Prevention, 2022-11, Vol.23 (11), p.3791-3799</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c2591-49e26cfe94720ac86cecb302980a2bc52ec5e721c0615daaabd353c7a65ef36f3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9930965/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9930965/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36444592$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nantasupha, Chalaithorn</creatorcontrib><creatorcontrib>Muangmool, Tanarat</creatorcontrib><creatorcontrib>Charoenkwan, Kittipat</creatorcontrib><title>Prognostic Factors for Advanced Epithelial Ovarian Cancer Following Primary Cytoreductive Surgery or Neoadjuvant Chemotherapy</title><title>Asian Pacific Journal of Cancer Prevention</title><addtitle>Asian Pac J Cancer Prev</addtitle><description>To examine the association between clinicopathological factors and survival in advanced epithelial ovarian, tubal, and primary peritoneal cancers patients who had primary cytoreductive surgery (CRS) and those that received neoadjuvant chemotherapy (NAC). Women who had CRS or NAC between 2008-2017 were included. Association between clinical characteristics, pretreatment imaging, serum markers, surgical and pathological factors, and disease recurrence/progression/death was examined in multivariable analysis. Two hundred and three women were recruited in this study (CRS 128 women and NAC 75 women). Median overall survival was 33.7 months for the CRS group and 27.9 months for the NAC group (p=0.04). Median progression-free survival was 14.9 months in the CRS group and 12.1 months in the NAC group (p=0.04). For the CRS group, factors independently associated with increased risk of death included primary peritoneal carcinoma (adjusted hazard ratio [aHR] 6.94), stable disease/progression at treatment completion (aHR 5.97), and initial tumor size of more than 12 cm (aHR 1.87). For the NAC group, stable disease/progression after complete treatment (aHR 6.45) and pre-treatment platelet to lymphocyte ratio of more than 310 (aHR 2.20) were significantly associated with an increased risk of death. NAC appeared to be a good alternative treatment for stage III/IV tubo-ovarian carcinoma. The worse survival outcome associated with primary peritoneal carcinoma and large initial tumor size in the patients who received CRS suggested that NAC could be an attractive option for those with these characteristics.</description><subject>Carcinoma, Ovarian Epithelial - drug therapy</subject><subject>Cytoreduction Surgical Procedures</subject><subject>Female</subject><subject>Genital Neoplasms, Male</subject><subject>Humans</subject><subject>Neoadjuvant Therapy</subject><subject>Ovarian Neoplasms - drug therapy</subject><subject>Ovarian Neoplasms - surgery</subject><subject>Prognosis</subject><issn>2476-762X</issn><issn>1513-7368</issn><issn>2476-762X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkdtKAzEQhoMoHqqvIHmBrjlsss2NUBbrAdGCCt6FaXa2jWw3Jbut9MJ3d9tq0asZZvi_GfgIueQskVyp7Go4fsjHiWBCJEImnCcyM_yAnIo00_1Mi_fDP_0JOWuaD8ZSNcjUMTmROk1TZcQp-RrHMK1D03pHR-DaEBtahkiHxQpqhwW9Wfh2hpWHij6vIHqoab7ZRDoKVRU-fT2l4-jnENc0X3d5LJau9SukL8s4xW7a0Z4wQPGx7JAtzWc4Dx0ywmJ9To5KqBq8-Kk98ja6ec3v-o_Pt_f58LHvhDK8nxoU2pVo0kwwcAPt0E0kE2bAQEycEugUZoI7prkqAGBSSCVdBlphKXUpe-R6x10sJ3MsHNZthMoudn_bAN7-39R-ZqdhZY2RzGjVAfQO4GJomojlPsuZ3QqxWyF2I8QKaTm3GyFd8PLv5X3s14D8BrnWjLo</recordid><startdate>20221101</startdate><enddate>20221101</enddate><creator>Nantasupha, Chalaithorn</creator><creator>Muangmool, Tanarat</creator><creator>Charoenkwan, Kittipat</creator><general>West Asia Organization for Cancer Prevention</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20221101</creationdate><title>Prognostic Factors for Advanced Epithelial Ovarian Cancer Following Primary Cytoreductive Surgery or Neoadjuvant Chemotherapy</title><author>Nantasupha, Chalaithorn ; Muangmool, Tanarat ; Charoenkwan, Kittipat</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2591-49e26cfe94720ac86cecb302980a2bc52ec5e721c0615daaabd353c7a65ef36f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Carcinoma, Ovarian Epithelial - drug therapy</topic><topic>Cytoreduction Surgical Procedures</topic><topic>Female</topic><topic>Genital Neoplasms, Male</topic><topic>Humans</topic><topic>Neoadjuvant Therapy</topic><topic>Ovarian Neoplasms - drug therapy</topic><topic>Ovarian Neoplasms - surgery</topic><topic>Prognosis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nantasupha, Chalaithorn</creatorcontrib><creatorcontrib>Muangmool, Tanarat</creatorcontrib><creatorcontrib>Charoenkwan, Kittipat</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Asian Pacific Journal of Cancer Prevention</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nantasupha, Chalaithorn</au><au>Muangmool, Tanarat</au><au>Charoenkwan, Kittipat</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prognostic Factors for Advanced Epithelial Ovarian Cancer Following Primary Cytoreductive Surgery or Neoadjuvant Chemotherapy</atitle><jtitle>Asian Pacific Journal of Cancer Prevention</jtitle><addtitle>Asian Pac J Cancer Prev</addtitle><date>2022-11-01</date><risdate>2022</risdate><volume>23</volume><issue>11</issue><spage>3791</spage><epage>3799</epage><pages>3791-3799</pages><issn>2476-762X</issn><issn>1513-7368</issn><eissn>2476-762X</eissn><abstract>To examine the association between clinicopathological factors and survival in advanced epithelial ovarian, tubal, and primary peritoneal cancers patients who had primary cytoreductive surgery (CRS) and those that received neoadjuvant chemotherapy (NAC). Women who had CRS or NAC between 2008-2017 were included. Association between clinical characteristics, pretreatment imaging, serum markers, surgical and pathological factors, and disease recurrence/progression/death was examined in multivariable analysis. Two hundred and three women were recruited in this study (CRS 128 women and NAC 75 women). Median overall survival was 33.7 months for the CRS group and 27.9 months for the NAC group (p=0.04). Median progression-free survival was 14.9 months in the CRS group and 12.1 months in the NAC group (p=0.04). For the CRS group, factors independently associated with increased risk of death included primary peritoneal carcinoma (adjusted hazard ratio [aHR] 6.94), stable disease/progression at treatment completion (aHR 5.97), and initial tumor size of more than 12 cm (aHR 1.87). For the NAC group, stable disease/progression after complete treatment (aHR 6.45) and pre-treatment platelet to lymphocyte ratio of more than 310 (aHR 2.20) were significantly associated with an increased risk of death. NAC appeared to be a good alternative treatment for stage III/IV tubo-ovarian carcinoma. The worse survival outcome associated with primary peritoneal carcinoma and large initial tumor size in the patients who received CRS suggested that NAC could be an attractive option for those with these characteristics.</abstract><cop>Thailand</cop><pub>West Asia Organization for Cancer Prevention</pub><pmid>36444592</pmid><doi>10.31557/APJCP.2022.23.11.3791</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2476-762X
ispartof Asian Pacific Journal of Cancer Prevention, 2022-11, Vol.23 (11), p.3791-3799
issn 2476-762X
1513-7368
2476-762X
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9930965
source MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Free E- Journals
subjects Carcinoma, Ovarian Epithelial - drug therapy
Cytoreduction Surgical Procedures
Female
Genital Neoplasms, Male
Humans
Neoadjuvant Therapy
Ovarian Neoplasms - drug therapy
Ovarian Neoplasms - surgery
Prognosis
title Prognostic Factors for Advanced Epithelial Ovarian Cancer Following Primary Cytoreductive Surgery or Neoadjuvant Chemotherapy
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T02%3A34%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prognostic%20Factors%20for%20Advanced%20Epithelial%20Ovarian%20Cancer%20Following%20Primary%20Cytoreductive%20Surgery%20or%20Neoadjuvant%20Chemotherapy&rft.jtitle=Asian%20Pacific%20Journal%20of%20Cancer%20Prevention&rft.au=Nantasupha,%20Chalaithorn&rft.date=2022-11-01&rft.volume=23&rft.issue=11&rft.spage=3791&rft.epage=3799&rft.pages=3791-3799&rft.issn=2476-762X&rft.eissn=2476-762X&rft_id=info:doi/10.31557/APJCP.2022.23.11.3791&rft_dat=%3Cpubmed_cross%3E36444592%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/36444592&rfr_iscdi=true